COMMUNIQUÉ DETAILS
MEDIA
No media uploaded.
INFO
About
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. It offers commercial clinical testing services, including routine clinical testing, such as tests for blood chemistries, complete blood cell counts, urinalyses, alcohol and other substance-abuse, and allergy, as well as routine microbiology testing, and pregnancy and other prenatal tests; anatomic pathology services for diagnosis of cancer and other diseases and medical conditions; gene-based and esoteric testing to establish a prognosis and to choose or monitor a therapeutic regimen; and testing services to employers for the detection of employee use of drugs-of-abuse. The company also provides risk assessment services for the life insurance industry; and develops and integrates clinical connectivity and data management solutions for healthcare organizations, physicians, and clinicians through its Care360 suite of products; and offers the ChartMaxx electronic document management system for hospitals. In addition, it offers provides central laboratory testing services in connection with clinical research trials on new drugs, vaccines, and certain medical devices. Further, the company develops and manufactures products that enable healthcare professionals to make healthcare diagnoses, including HerpeSelect ELISA tests that detect patient antibodies to certain types of herpes simplex virus, and sells to academic medical centers, hospitals, and commercial laboratories; point-of-care blood testing products; and InSure fecal immunochemical test for screening for colorectal cancer. Quest Diagnostics Incorporated offers its diagnostic testing services to patients, physicians, hospitals, employers, governmental institutions, and other commercial clinical laboratories through a network of laboratories and patient service centers. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Madison, New Jersey.
- W COMPANY SITE
- P 973-520-2700
Press Release $DGX Quest Diagnostics Inc.
Quest Diagnostics/Berkeley HeartLab and LabCorp To Offer Presage® ST2 Assay for Heart Failure Patients
SAN DIEGO--(BUSINESS WIRE)-- Critical Diagnostics, a U.S.-based biomarker company focused on cardiovascular diseases and Quest Diagnostics (NYSE: DGX) and its subsidiary Berkeley HeartLab, announced today an agreement under which both Quest and Berkeley HeartLab will offer ST2 testing services based on Critical Diagnostics’ Presage ST2 Assay. Critical Diagnostics has also signed an agreement with Laboratory Corporation of America (NYSE: LH), better known as LabCorp, to offer testing of the Presage ST2 Assay. Combined, these two diagnostic market leaders perform some one-and-a-half million tests per day.
The Presage ST2 Assay is FDA cleared for use in assessing the prognosis of patients diagnosed with chronic heart failure. According to the American Heart Association, heart failure affects some 6 million Americans with 600,000 new diagnoses each year.
Clinical studies have demonstrated that high levels of soluble ST2 are predictive of adverse patient outcomes and death. For instance, chronic heart failure patients with ST2 levels above the standard cutpoint, have a three times greater risk of 30-day rehospitalization or mortality.
Unlike many other cardiac biomarkers, ST2 levels change quickly in response to changes in the patient’s condition—thus helping physicians make informed decisions on an appropriate course of action to take and, if needed, to quickly adjust care.
Furthermore, prognostic information from soluble ST2 is independent of and complimentary to natriuretic peptide markers like BNP and NT-proBNP, and unlike natriuretic peptide markers, is not adversely affected by such confounding factors as age, gender, body mass index and impaired renal failure.
“We are extremely proud to be associated with these two exceptional organizations,” said James Snider, President of Critical Diagnostics. “The Quest/Berkeley HeartLab and LabCorp collaborations, in addition to our existing clinical lab relationships, mean that physicians nationwide will now have access to Presage ST2 testing to help guide and improve heart failure patient outcomes.”
About Critical Diagnostics and ST2
Critical Diagnostics (www.criticaldiagnostics.com) develops novel biomarkers to help physicians optimize patient care in cardiovascular diseases, while containing healthcare costs. The Presage ST2 Assay has been CE Marked and cleared by the US FDA.
About Quest Diagnostics and Berkeley HeartLab
Quest Diagnostics is the world's leading provider of diagnostic testing, offering the broadest access to diagnostic testing services through its network of laboratories and patient service centers. Berkeley HeartLab is the company's business unit specializing in advanced cardiovascular disease testing.
About LabCorp
LabCorp, with corporate headquarters in Burlington, NC, and more than 30,000 employees nationwide, has some 220,000 clients including physician offices, hospitals, managed care organizations, and biotechnology and pharmaceutical companies.
Critical Diagnostics
Dennis Dalangin, 877-700-1250
VP Marketing
ddalangin@criticaldiagnostics.com
Source: Critical Diagnostics